2,4-thiazolidinedione has been researched along with Body Weight in 20 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of dietary energy level and 2,4-thiazolidinedione (TZD) injection on feed intake, body fatness, blood biomarkers and TZD concentrations, genes related to insulin sensitivity in adipose tissue (AT) and skeletal muscle, and peroxisome proliferator-activated receptor gamma (PPARG) protein in subcutaneous AT (SAT) were evaluated in Holstein cows." | 7.81 | Insulin Sensitivity in Adipose and Skeletal Muscle Tissue of Dairy Cows in Response to Dietary Energy Level and 2,4-Thiazolidinedione (TZD). ( Drackley, JK; Hosseini, A; Iqbal, Z; Kesser, J; Loor, JJ; Mora, O; Sauerwein, H; Tariq, MR; Trevisi, E; Trindade da Rosa, F, 2015) |
| " Long-term (2 weeks) oral treatment with the rexinoids LG100268 and LG100324 reduced food intake and body weight gain, whereas rosiglitazone (BRL49653) tended to increase both food intake and weight gain." | 7.70 | The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. ( Cawthorne, MA; Emilsson, V; Heyman, R; Liu, YL; O'Dowd, J; Sennitt, M; Wang, S, 2000) |
| " Nine of the eleven studies showed significant decrease in body weight among participants in the exenatide group compared with placebo or control group while the other two studies did not report statistically significant differences in body weight." | 4.93 | The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review. ( Ojo, O, 2016) |
| "The effects of dietary energy level and 2,4-thiazolidinedione (TZD) injection on feed intake, body fatness, blood biomarkers and TZD concentrations, genes related to insulin sensitivity in adipose tissue (AT) and skeletal muscle, and peroxisome proliferator-activated receptor gamma (PPARG) protein in subcutaneous AT (SAT) were evaluated in Holstein cows." | 3.81 | Insulin Sensitivity in Adipose and Skeletal Muscle Tissue of Dairy Cows in Response to Dietary Energy Level and 2,4-Thiazolidinedione (TZD). ( Drackley, JK; Hosseini, A; Iqbal, Z; Kesser, J; Loor, JJ; Mora, O; Sauerwein, H; Tariq, MR; Trevisi, E; Trindade da Rosa, F, 2015) |
| "Over a 20-year period, patients on dapagliflozin were projected to experience relative reductions in the incidence of myocardial infarction (MI), stroke, CV death, and all-cause death of 13." | 3.80 | Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. ( Alperin, P; Cohen, M; Dziuba, J; Goswami, D; Grossman, HL; Hardy, E; Iloeje, U; Perlstein, I; Racketa, J, 2014) |
| " We found that mice with CD knockout of this receptor were resistant to the rosiglitazone- (RGZ) induced increases in body weight and plasma volume expansion found in control mice expressing PPARgamma in the CD." | 3.73 | Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. ( Gonzalez, FJ; Kohan, DE; Nelson, RD; Yang, T; Zhang, A; Zhang, H, 2005) |
| "Combination of insulin and rosiglitazone is effective in massively obese patients with Type 2 diabetes, though there is a high incidence of peripheral oedema." | 3.71 | Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes. ( Akarca, C; Barton, DM; Baskar, V; Buch, HN; Kamalakannan, D; Singh, BM, 2002) |
| " Long-term (2 weeks) oral treatment with the rexinoids LG100268 and LG100324 reduced food intake and body weight gain, whereas rosiglitazone (BRL49653) tended to increase both food intake and weight gain." | 3.70 | The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat. ( Cawthorne, MA; Emilsson, V; Heyman, R; Liu, YL; O'Dowd, J; Sennitt, M; Wang, S, 2000) |
| "The purpose of this study was to assess the efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor vildagliptin in combination with the thiazolidinedione (TZD) pioglitazone in patients with type 2 diabetes (T2DM)." | 2.73 | Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. ( Baron, MA; Dejager, S; Garber, AJ; Rochotte, E; Schweizer, A, 2007) |
| " However, their use has been curtailed by substantial adverse effects on weight, bone, heart, and hemodynamic balance." | 1.48 | PPARγ deacetylation dissociates thiazolidinedione's metabolic benefits from its adverse effects. ( Area-Gomez, E; Chan, M; Creusot, RJ; Fan, L; Fu, W; Ji, R; Kon, N; Kraakman, MJ; Larrea, D; Liu, Q; Namwanje, M; Postigo-Fernandez, J; Qiang, L, 2018) |
| " In this study, we examined the changes in both cancellous and cortical bone of 6-month-old male mice treated with darglitazone, a potent and selective PPARgamma agonist, at 10 mg/kg/day by dosing the compound in a food mixture for 2 or 8 weeks." | 1.33 | Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice. ( Brown, TA; Healy, DR; Ke, HZ; Li, M; Li, Y; Pan, LC; Robinson, BS; Simmons, HA, 2006) |
| "Rosiglitazone treatment normalized the insulin resistance and restored GLUT4 protein levels in obese rat hearts." | 1.31 | Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. ( Buckingham, RE; Clarke, K; Cole, MA; Desrois, M; Draper, NJ; Sidell, RJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.00) | 18.2507 |
| 2000's | 14 (70.00) | 29.6817 |
| 2010's | 5 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kraakman, MJ | 1 |
| Liu, Q | 1 |
| Postigo-Fernandez, J | 1 |
| Ji, R | 1 |
| Kon, N | 1 |
| Larrea, D | 1 |
| Namwanje, M | 1 |
| Fan, L | 1 |
| Chan, M | 1 |
| Area-Gomez, E | 1 |
| Fu, W | 1 |
| Creusot, RJ | 1 |
| Qiang, L | 1 |
| Yang, SC | 1 |
| Tseng, HL | 1 |
| Shieh, KR | 1 |
| Dziuba, J | 1 |
| Alperin, P | 1 |
| Racketa, J | 1 |
| Iloeje, U | 1 |
| Goswami, D | 1 |
| Hardy, E | 1 |
| Perlstein, I | 1 |
| Grossman, HL | 1 |
| Cohen, M | 1 |
| Hosseini, A | 1 |
| Tariq, MR | 1 |
| Trindade da Rosa, F | 1 |
| Kesser, J | 1 |
| Iqbal, Z | 1 |
| Mora, O | 1 |
| Sauerwein, H | 1 |
| Drackley, JK | 1 |
| Trevisi, E | 1 |
| Loor, JJ | 1 |
| Ojo, O | 1 |
| Yu, JG | 1 |
| Javorschi, S | 1 |
| Hevener, AL | 1 |
| Kruszynska, YT | 1 |
| Norman, RA | 1 |
| Sinha, M | 1 |
| Olefsky, JM | 1 |
| Fonseca, V | 1 |
| Hollenberg, NK | 1 |
| Wellen, KE | 1 |
| Uysal, KT | 1 |
| Wiesbrock, S | 1 |
| Yang, Q | 1 |
| Chen, H | 1 |
| Hotamisligil, GS | 1 |
| Zhang, H | 1 |
| Zhang, A | 1 |
| Kohan, DE | 1 |
| Nelson, RD | 1 |
| Gonzalez, FJ | 1 |
| Yang, T | 1 |
| Schwartz, AV | 1 |
| Sellmeyer, DE | 1 |
| Vittinghoff, E | 1 |
| Palermo, L | 1 |
| Lecka-Czernik, B | 1 |
| Feingold, KR | 1 |
| Strotmeyer, ES | 1 |
| Resnick, HE | 1 |
| Carbone, L | 1 |
| Beamer, BA | 1 |
| Park, SW | 1 |
| Lane, NE | 1 |
| Harris, TB | 1 |
| Cummings, SR | 1 |
| Li, M | 1 |
| Pan, LC | 1 |
| Simmons, HA | 1 |
| Li, Y | 1 |
| Healy, DR | 1 |
| Robinson, BS | 1 |
| Ke, HZ | 1 |
| Brown, TA | 1 |
| Garber, AJ | 1 |
| Schweizer, A | 1 |
| Baron, MA | 1 |
| Rochotte, E | 2 |
| Dejager, S | 1 |
| Bolli, G | 1 |
| Dotta, F | 1 |
| Cohen, SE | 1 |
| Fürnsinn, C | 1 |
| Brunmair, B | 1 |
| Meyer, M | 1 |
| Neschen, S | 1 |
| Furtmüller, R | 1 |
| Roden, M | 1 |
| Kühnle, HF | 1 |
| Nowotny, P | 1 |
| Schneider, B | 1 |
| Waldhäusl, W | 1 |
| Suzuki, A | 1 |
| Yasuno, T | 1 |
| Kojo, H | 1 |
| Hirosumi, J | 1 |
| Mutoh, S | 1 |
| Notsu, Y | 1 |
| Emilsson, V | 1 |
| O'Dowd, J | 1 |
| Wang, S | 1 |
| Liu, YL | 1 |
| Sennitt, M | 1 |
| Heyman, R | 1 |
| Cawthorne, MA | 1 |
| Sidell, RJ | 1 |
| Cole, MA | 1 |
| Draper, NJ | 1 |
| Desrois, M | 1 |
| Buckingham, RE | 1 |
| Clarke, K | 1 |
| Buch, HN | 1 |
| Baskar, V | 1 |
| Barton, DM | 1 |
| Kamalakannan, D | 1 |
| Akarca, C | 1 |
| Singh, BM | 1 |
| Humphries, PS | 1 |
| Bailey, S | 1 |
| Almaden, JV | 1 |
| Barnum, SJ | 1 |
| Carlson, TJ | 1 |
| Christie, LC | 1 |
| Do, QQ | 1 |
| Fraser, JD | 1 |
| Hess, M | 1 |
| Kellum, J | 1 |
| Kim, YH | 1 |
| McClellan, GA | 1 |
| Ogilvie, KM | 1 |
| Simmons, BH | 1 |
| Skalitzky, D | 1 |
| Sun, S | 1 |
| Wilhite, D | 1 |
| Zehnder, LR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes[NCT00099853] | Phase 3 | 362 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes[NCT00237237] | Phase 3 | 588 participants | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for 2,4-thiazolidinedione and Body Weight
| Article | Year |
|---|---|
The Use of Exenatide in Managing Markers of Cardiovascular Risk in Patients with Type 2 Diabetes: A Systematic Review.
Topics: Biomarkers; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exenatide; Female; Glyc | 2016 |
Effect of thiazolidinediones on body weight in patients with diabetes mellitus.
Topics: Adipose Tissue; Body Weight; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Diabetes Melli | 2003 |
Considerations for management of fluid dynamic issues associated with thiazolidinediones.
Topics: Body Fluids; Body Weight; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Di | 2003 |
3 trials available for 2,4-thiazolidinedione and Body Weight
| Article | Year |
|---|---|
The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
Topics: Adiponectin; Adult; Animals; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gluc | 2002 |
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
Topics: Adamantane; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase | 2007 |
Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.
Topics: Adamantane; Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-B | 2008 |
14 other studies available for 2,4-thiazolidinedione and Body Weight
| Article | Year |
|---|---|
PPARγ deacetylation dissociates thiazolidinedione's metabolic benefits from its adverse effects.
Topics: Acetylation; Adipose Tissue, White; Animals; Body Weight; Energy Metabolism; Female; Hypoglycemic Ag | 2018 |
Circadian-clock system in mouse liver affected by insulin resistance.
Topics: Animals; Blood Glucose; Body Weight; Circadian Clocks; Circadian Rhythm; Diabetes Mellitus, Experime | 2013 |
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Topics: Amputation, Surgical; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascul | 2014 |
Insulin Sensitivity in Adipose and Skeletal Muscle Tissue of Dairy Cows in Response to Dietary Energy Level and 2,4-Thiazolidinedione (TZD).
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Adiposity; Animal Feed; Animals; Biopsy; Blood Glucose; Body | 2015 |
Interaction of tumor necrosis factor-alpha- and thiazolidinedione-regulated pathways in obesity.
Topics: Adipose Tissue; Animals; Blood Glucose; Body Weight; Drug Interactions; Hypoglycemic Agents; Insulin | 2004 |
Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.
Topics: Aldosterone; Animals; Biological Transport; Body Weight; Coloring Agents; Diabetes Mellitus, Type 2; | 2005 |
Thiazolidinedione use and bone loss in older diabetic adults.
Topics: Absorptiometry, Photon; Aged; Blood Glucose; Body Weight; Bone Density; Cohort Studies; Diabetes Mel | 2006 |
Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice.
Topics: Adipogenesis; Alkaline Phosphatase; Animals; Body Weight; Bone and Bones; Bone Density; Bone Marrow | 2006 |
Chronic and acute effects of thiazolidinediones BM13.1258 and BM15.2054 on rat skeletal muscle glucose metabolism.
Topics: Animals; Biological Transport; Body Weight; Cell Line; Deoxyglucose; Glucose; In Vitro Techniques; I | 1999 |
Alteration in expression profiles of a series of diabetes-related genes in db/db mice following treatment with thiazolidinediones.
Topics: Adipocytes; Animals; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus, Experimental; Female; | 2000 |
The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat.
Topics: Adipose Tissue, Brown; Animals; Body Weight; Carrier Proteins; Eating; Ion Channels; Membrane Protei | 2000 |
Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Heart; Heart Rate; Hypoglycemic Agents; Insulin | 2002 |
Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes.
Topics: Adult; Aged; Body Mass Index; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Drug T | 2002 |
Pyridine-3-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.
Topics: Animals; Blood Glucose; Body Weight; Cell Line, Tumor; Diabetes Mellitus; Ether; Humans; Hypoglycemi | 2006 |